September 30, 2024 (v1)
Journal article
Purpose of review This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle. Recent findings Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent...
Uploaded on: October 26, 2024